XLON
PYC
Market cap2mUSD
Oct 09, Last price
0.48GBP
1D
-9.52%
1Q
0.00%
Jan 2017
-75.64%
IPO
-99.80%
Name
Physiomics PLC
Chart & performance
P/E
—
P/S
2.04
EPS
—
Div yield, %
—
Shrs. gr., 5y
26.43%
Rev. gr., 5y
-0.38%
Revenues
784k
+44.32%
Net income
-415k
L-31.85%
CFO
-546k
L-0.36%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Founded in 2001 and headquartered in Oxford, UK, Physiomics Plc offers expert consulting services to pharmaceutical enterprises across the United Kingdom, the United States, and the European Union. The company's core specialization lies in outsourced quantitative pharmacology and computational biology. They deliver comprehensive modeling, simulation, and data analysis services primarily focused on oncology research and development, utilizing their proprietary Virtual Tumour predictive software. Additionally, Physiomics is engaged in developing innovative technologies for applications within the field of personalized medicine.
Key people
Paul Bernard Harper
Non-Executive Chairman of the Board · since 2007
James Millen
Chief Executive Officer · since 2016
Christophe David Chassagnole
Chief Operating Officer, Executive Director
Elizabeth King
Company Secretary · since 2014
Headquarters & legal address
MILTON PARK INNOVATION CENTRE
99 PARK DRIVE
MILTON PARK
ABINGDON, OXF OX14 4RY
GB
99 PARK DRIVE
MILTON PARK
ABINGDON, OXF OX14 4RY
GB
Valuation
Title GBP in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑06 | 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||